[go: up one dir, main page]

PE20090763A1 - Polipetidos, dominios variables de anticuerpos y antagonistas - Google Patents

Polipetidos, dominios variables de anticuerpos y antagonistas

Info

Publication number
PE20090763A1
PE20090763A1 PE2008000943A PE2008000943A PE20090763A1 PE 20090763 A1 PE20090763 A1 PE 20090763A1 PE 2008000943 A PE2008000943 A PE 2008000943A PE 2008000943 A PE2008000943 A PE 2008000943A PE 20090763 A1 PE20090763 A1 PE 20090763A1
Authority
PE
Peru
Prior art keywords
antagonists
antibodies
variable domains
polypetides
dab
Prior art date
Application number
PE2008000943A
Other languages
English (en)
Inventor
Laurent Stephane Anne Therese Jespers
Malgorzata Pupecka
Ian Tomlinson
Carolyn Enever
Original Assignee
Domantis Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB0724331.4A external-priority patent/GB0724331D0/en
Application filed by Domantis Ltd filed Critical Domantis Ltd
Publication of PE20090763A1 publication Critical patent/PE20090763A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/005—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies constructed by phage libraries
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/06—Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/04—Artificial tears; Irrigation solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/543—Mucosal route intranasal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/544—Mucosal route to the airways
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Pulmonology (AREA)
  • Virology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Communicable Diseases (AREA)
  • Otolaryngology (AREA)
  • Oncology (AREA)
  • Rheumatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Dispersion Chemistry (AREA)
  • Cardiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Transplantation (AREA)
  • Toxicology (AREA)
  • Pain & Pain Management (AREA)

Abstract

REFERIDO A LOS DOMINIOS VARIABLES SIMPLES (dAb) DE POLIPEPTIDOS Y ANTICUERPOS DEL anti-TNFR1 TAL COMO LA INMUNOGLOBULINA DEL RECEPTOR TIPO 1 DEL ANTICUERPO TNFa (TNFR1;p55), QUE COMPRENDE UNA SECUENCIA DE AMINOACIDOS AL 93% IDENTICA A LA SECUENCIA DE AMINOACIDOS DE DOM1h-131-206; TAL COMO ACIDO ASPARTICO EN POSICION 53 E HISTIDINA EN POSICION 91, QUE SON RESISTENTES A LA DEGRADACION DE UNA PROTEASA. LOS POLIPEPTIDOS dAb Y ANTAGONISTAS SON UTILES COMO AGENTES TERAPEUTICOS Y/O PROFILACTICOS PARA COMBATIR LAS PROTEASAS CUANDO SE ADMINISTRAN POR VIA PULMONAR, ORAL O GASTRICA ASI COMO PARA EL TRATAMIENTO DE ENFERMEDADES INFLAMATORIAS TAL COMO ARTRITIS O COPD
PE2008000943A 2007-06-06 2008-06-04 Polipetidos, dominios variables de anticuerpos y antagonistas PE20090763A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US93363207P 2007-06-06 2007-06-06
GBGB0724331.4A GB0724331D0 (en) 2007-12-13 2007-12-13 Compositions for pulmonary delivery

Publications (1)

Publication Number Publication Date
PE20090763A1 true PE20090763A1 (es) 2009-07-10

Family

ID=39791116

Family Applications (3)

Application Number Title Priority Date Filing Date
PE2008000943A PE20090763A1 (es) 2007-06-06 2008-06-04 Polipetidos, dominios variables de anticuerpos y antagonistas
PE2008000944A PE20090323A1 (es) 2007-06-06 2008-06-04 Fraccion de anticuerpo y anticuerpo antagonista de il-1r1
PE2008000940A PE20090322A1 (es) 2007-06-06 2008-06-04 Fraccion de anticuerpo y anticuerpo antagonista del factor de crecimiento endotelial vascular

Family Applications After (2)

Application Number Title Priority Date Filing Date
PE2008000944A PE20090323A1 (es) 2007-06-06 2008-06-04 Fraccion de anticuerpo y anticuerpo antagonista de il-1r1
PE2008000940A PE20090322A1 (es) 2007-06-06 2008-06-04 Fraccion de anticuerpo y anticuerpo antagonista del factor de crecimiento endotelial vascular

Country Status (31)

Country Link
US (5) US8398979B2 (es)
EP (5) EP2746291B1 (es)
JP (3) JP5325211B2 (es)
KR (4) KR20100018040A (es)
CN (4) CN101883788A (es)
AR (3) AR066847A1 (es)
AU (4) AU2008259590A1 (es)
BR (3) BRPI0813899A2 (es)
CA (6) CA2683791A1 (es)
CL (3) CL2008001674A1 (es)
CO (2) CO6251322A2 (es)
CR (2) CR11194A (es)
CY (1) CY1116762T1 (es)
DK (1) DK2162467T3 (es)
DO (1) DOP2009000268A (es)
EA (5) EA200901494A1 (es)
ES (1) ES2546943T3 (es)
HR (1) HRP20151024T1 (es)
HU (1) HUE025899T2 (es)
IL (2) IL201398A0 (es)
MA (2) MA31403B1 (es)
MX (4) MX2009013137A (es)
NZ (1) NZ581372A (es)
PE (3) PE20090763A1 (es)
PL (1) PL2162467T3 (es)
PT (1) PT2162467E (es)
SG (2) SG182151A1 (es)
SI (1) SI2162467T1 (es)
TW (6) TW200911834A (es)
WO (3) WO2008149148A2 (es)
ZA (1) ZA200908470B (es)

Families Citing this family (66)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005289809A (ja) 2001-10-24 2005-10-20 Vlaams Interuniversitair Inst Voor Biotechnologie Vzw (Vib Vzw) 突然変異重鎖抗体
EP2479191A3 (en) 2005-05-18 2013-03-13 Ablynx N.V. Improved nanobodiesTM against tumor necrosis factor-alpha
DE102005023617A1 (de) 2005-05-21 2006-11-23 Aspre Ag Verfahren zum Mischen von Farben in einem Display
SG182170A1 (en) * 2007-06-06 2012-07-30 Domantis Ltd Polypeptides, antibody variable domains and antagonists
CA2683791A1 (en) 2007-06-06 2008-12-11 Domantis Limited Polypeptides, antibody variable domains & antagonists
GB0724331D0 (en) * 2007-12-13 2008-01-23 Domantis Ltd Compositions for pulmonary delivery
JP2011506396A (ja) * 2007-12-13 2011-03-03 グラクソ グループ リミテッド 肺送達用組成物
WO2009127691A1 (en) 2008-04-17 2009-10-22 Ablynx N.V. Peptides capable of binding to serum proteins and compounds, constructs and polypeptides comprising the same
MX347972B (es) 2008-06-25 2017-05-22 Esbatech Alcon Biomed Res Unit Anticuerpos estables y solubles que inhiben el vegf.
US8268314B2 (en) 2008-10-08 2012-09-18 Hoffmann-La Roche Inc. Bispecific anti-VEGF/anti-ANG-2 antibodies
KR20110091777A (ko) * 2008-11-26 2011-08-12 글락소 그룹 리미티드 폴리펩티드, 항체 가변 도메인 및 길항제
WO2010081787A1 (en) 2009-01-14 2010-07-22 Domantis Limited IMPROVED TNFα ANTAGONISM, PROPHYLAXIS & THERAPY WITH REDUCED ORGAN NECROSIS
BRPI1008705B1 (pt) 2009-02-19 2021-05-25 Glaxo Group Limited Domínio variável único da imunoglobulina anti-soro albumina, ligante multiespecífico compreendendo o dito domínio, proteína de fusão fundida ao dito domínio, composição, ácido nucleico e vetor compreendendo o dito ácido nucleico
JP2012517818A (ja) 2009-02-19 2012-08-09 グラクソ グループ リミテッド 改善された抗ｔｎｆｒ１ポリペプチド、抗体可変ドメインおよびアンタゴニスト
CN102405233B (zh) 2009-02-19 2014-11-26 葛兰素集团有限公司 改良的抗血清清蛋白结合变体
WO2010097385A1 (en) 2009-02-24 2010-09-02 Glaxo Group Limited Antigen-binding constructs
WO2011006914A2 (en) 2009-07-16 2011-01-20 Glaxo Group Limited Antagonists, uses & methods for partially inhibiting tnfr1
KR20120038494A (ko) 2009-07-16 2012-04-23 글락소 그룹 리미티드 개선된 항-혈청 알부민 결합 단일 가변 도메인
CN102655875A (zh) * 2009-10-14 2012-09-05 爱勒让治疗公司 改善的拟肽大环化合物
NZ599114A (en) 2009-10-27 2014-09-26 Glaxo Group Ltd Stable anti-tnfr1 polypeptides, antibody variable domains & antagonists
JP2013518853A (ja) 2010-02-05 2013-05-23 アブリンクス エン．ヴェー． 血清アルブミンと結合することが可能なペプチド並びにこれを含む化合物、構築物及びポリペプチド
EA201291009A1 (ru) 2010-05-20 2013-05-30 Глаксо Груп Лимитед Улучшенные связывающие варианты против сывороточного альбумина
JP2013538566A (ja) * 2010-08-13 2013-10-17 グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッド 改良された抗血清アルブミン結合変異体
JP2013537421A (ja) * 2010-08-20 2013-10-03 グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッド 改良された抗血清アルブミン結合変異体
US8859739B2 (en) 2010-09-16 2014-10-14 Baliopharm Ag Anti-huTNFR1 antibody and methods of use thereof for treatment
US20130266567A1 (en) 2010-12-01 2013-10-10 Haren Arulanantham Anti-serum albumin binding single variable domains
JP2014505698A (ja) * 2011-02-02 2014-03-06 グラクソ グループ リミテッド 新規抗原結合タンパク質
US9527925B2 (en) 2011-04-01 2016-12-27 Boehringer Ingelheim International Gmbh Bispecific binding molecules binding to VEGF and ANG2
US10400029B2 (en) 2011-06-28 2019-09-03 Inhibrx, Lp Serpin fusion polypeptides and methods of use thereof
RU2727452C1 (ru) * 2011-06-28 2020-07-21 Инхибркс, Инк. Слитые серпиновые полипептиды и способы их применения
CN103842380A (zh) 2011-07-27 2014-06-04 葛兰素集团有限公司 融合至Fc结构域的抗VEGF单可变结构域
KR102162413B1 (ko) * 2011-08-17 2020-10-07 글락소 그룹 리미티드 변형된 단백질 및 펩티드
GB2497138A (en) * 2011-12-02 2013-06-05 Randox Lab Ltd Biomarkers for stroke and stroke subtype diagnosis.
HRP20181595T1 (hr) 2012-07-13 2018-12-14 Roche Glycart Ag Bispecifična anti-vegf/anti-ang-2 protutijela i njihova upotreba u liječenju očnih krvožilnih bolesti
WO2014111550A1 (en) 2013-01-17 2014-07-24 Glaxosmithkline Intellectual Property Development Limited Modified anti-serum albumin binding proteins
SG11201505388QA (en) 2013-01-31 2015-08-28 Glaxo Group Ltd Method of producing a protein
US9840553B2 (en) 2014-06-28 2017-12-12 Kodiak Sciences Inc. Dual PDGF/VEGF antagonists
AR103173A1 (es) 2014-12-22 2017-04-19 Novarits Ag Productos farmacéuticos y composiciones líquidas estables de anticuerpos il-17
MA41374A (fr) * 2015-01-20 2017-11-28 Cytomx Therapeutics Inc Substrats clivables par métalloprotéase matricielle et clivables par sérine protéase et procédés d'utilisation de ceux-ci
KR20250057128A (ko) 2015-12-30 2025-04-28 코디악 사이언시스 인코포레이티드 항체 및 이의 접합체
GB201617622D0 (en) * 2016-10-18 2016-11-30 VIB VZW and Universiteit Gent Means and methods to treat inflammation
RU2625010C1 (ru) * 2016-11-10 2017-07-11 Илья Петрович Приколаб Экспрессионный плазмидный вектор для экспрессии активной формы TNFR1-Fc и способ получения рекомбинантного белка
CA3041279A1 (en) 2016-11-28 2018-05-31 Chugai Seiyaku Kabushiki Kaisha Antigen-binding domain, and polypeptide including conveying section
US12060654B2 (en) 2016-11-28 2024-08-13 Chugai Seiyaku Kabushiki Kaisha Ligand-binding molecule having adjustable ligand binding activity
UY37651A (es) * 2017-03-31 2018-10-31 Swedish Orphan Biovitrum Ab Publ Polipéptido de unión al il-1r-i
JP7261232B2 (ja) * 2017-11-01 2023-04-19 アロジーン セラピューティクス，インコーポレイテッド 改変カスパーゼ－９ポリペプチドおよびその使用方法
EP3719036A4 (en) 2017-11-28 2021-09-08 Chugai Seiyaku Kabushiki Kaisha LIGAND BINDING MOLECULE HAVING ADJUSTABLE LIGAND BINDING ACTIVITY
SG11202004897XA (en) 2017-11-28 2020-06-29 Chugai Pharmaceutical Co Ltd Polypeptide including antigen-binding domain and carrying section
JP2021514656A (ja) 2018-03-02 2021-06-17 コディアック サイエンシーズ インコーポレイテッドＫｏｄｉａｋ Ｓｃｉｅｎｃｅｓ Ｉｎｃ． Ｉｌ−６抗体ならびにその融合構築物およびコンジュゲート
JP7414736B2 (ja) 2018-05-30 2024-01-16 中外製薬株式会社 アグリカン結合ドメインおよび運搬部分を含むポリペプチド
WO2019230866A1 (en) * 2018-05-30 2019-12-05 Chugai Seiyaku Kabushiki Kaisha Polypeptide comprising il-1r1 binding domain and carrying moiety
PL3623798T3 (pl) * 2018-09-13 2022-03-28 Euroimmun Medizinische Labordiagnostika Ag Sposób i urządzenie do wykrywania i przedstawiania obrazu immunofluorescencyjnego próbki biologicznej
EP3870331B1 (en) * 2018-10-25 2025-07-23 F. Hoffmann-La Roche AG Modification of antibody fcrn binding
AU2019394972A1 (en) 2018-12-06 2021-06-03 Cytomx Therapeutics, Inc. Matrix metalloprotease-cleavable and serine or cysteine protease-cleavable substrates and methods of use thereof
CN111454366B (zh) * 2019-01-21 2023-06-16 中国科学院深圳先进技术研究院 一种融合蛋白及其应用
JP7315967B2 (ja) * 2019-01-31 2023-07-27 積水メディカル株式会社 生物学的試料中の遊離ａｉｍの免疫学的分析方法及び測定キット
US11912784B2 (en) 2019-10-10 2024-02-27 Kodiak Sciences Inc. Methods of treating an eye disorder
JP7473398B2 (ja) * 2020-05-28 2024-04-23 シスメックス株式会社 キャリブレータ、複合体、及びＩｇＡ凝集体を測定する方法
IL300930A (en) * 2020-08-27 2023-04-01 Enosi Therapeutics Corp Methods and compositions for the treatment of autoimmune diseases and cancer
WO2022117569A1 (en) 2020-12-02 2022-06-09 Oncurious Nv A ccr8 antagonist antibody in combination with a lymphotoxin beta receptor agonist antibody in therapy against cancer
CN115181751A (zh) * 2021-04-02 2022-10-14 苏州博腾生物制药有限公司 靶向白蛋白的嵌合抗原受体及其使用方法
CN114657162B (zh) * 2022-03-04 2023-06-16 华南理工大学 一种具有血管内皮细胞保护功能的抗氧化五肽及其应用
CN115112704B (zh) * 2022-06-21 2025-07-15 中特检验集团有限公司 一种光热发电有机热载体热稳定性检测方法
JP7459354B2 (ja) 2022-07-08 2024-04-01 ノヴォ ノルディスク アー／エス ＦＶＩＩＩ（ａ）の代わりとなることができる非常に効力があるＩＳＶＤ化合物
WO2025049818A1 (en) 2023-08-29 2025-03-06 Enosi Therapeutics Corporation Tnfr1 antagonists lacking agonist activity and uses thereof
CN119909772B (zh) * 2025-04-01 2025-06-20 安徽一帆新材料科技有限公司 用于净水的再生阴树脂及其制备方法

Family Cites Families (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2148299B (en) 1983-09-01 1988-01-06 Hybritech Inc Antibody compositions of therapeutic agents having an extended serum half-life
AU600575B2 (en) 1987-03-18 1990-08-16 Sb2, Inc. Altered antibodies
GB8725529D0 (en) 1987-10-30 1987-12-02 Delta Biotechnology Ltd Polypeptides
JP3095168B2 (ja) 1988-02-05 2000-10-03 エル． モリソン，シェリー ドメイン‐変性不変部を有する抗体
AU4308689A (en) 1988-09-02 1990-04-02 Protein Engineering Corporation Generation and selection of recombinant varied binding proteins
JP2919890B2 (ja) 1988-11-11 1999-07-19 メディカル リサーチ カウンスル 単一ドメインリガンド、そのリガンドからなる受容体、その製造方法、ならびにそのリガンドおよび受容体の使用
ATE92107T1 (de) 1989-04-29 1993-08-15 Delta Biotechnology Ltd N-terminale fragmente von menschliches serumalbumin enthaltenden fusionsproteinen.
CA2016842A1 (en) 1989-05-16 1990-11-16 Richard A. Lerner Method for tapping the immunological repertoire
US5143854A (en) 1989-06-07 1992-09-01 Affymax Technologies N.V. Large scale photolithographic solid phase synthesis of polypeptides and receptor binding screening thereof
US5977307A (en) 1989-09-07 1999-11-02 Alkermes, Inc. Transferrin receptor specific ligand-neuropharmaceutical agent fusion proteins
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
US6172197B1 (en) 1991-07-10 2001-01-09 Medical Research Council Methods for producing members of specific binding pairs
JPH06508511A (ja) 1990-07-10 1994-09-29 ケンブリッジ　アンティボディー　テクノロジー　リミティド 特異的な結合ペアーの構成員の製造方法
ATE158021T1 (de) 1990-08-29 1997-09-15 Genpharm Int Produktion und nützung nicht-menschliche transgentiere zur produktion heterologe antikörper
AU663300B2 (en) 1990-12-06 1995-10-05 Affymetrix, Inc. Very large scale immobilized polymer synthesis
DE69233745D1 (de) 1991-12-02 2008-10-23 Cambridge Antibody Tech Herstellung von Autoantikörpern auf Phagenoberflächen ausgehend von Antikörpersegmentbibliotheken
US5733743A (en) 1992-03-24 1998-03-31 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
WO1994029351A2 (en) 1993-06-16 1994-12-22 Celltech Limited Antibodies
US5702892A (en) 1995-05-09 1997-12-30 The United States Of America As Represented By The Department Of Health And Human Services Phage-display of immunoglobulin heavy chain libraries
AU725609C (en) 1995-08-18 2002-01-03 Morphosys Ag Protein/(poly)peptide libraries
CN103275221B (zh) * 1996-02-09 2016-08-17 艾伯维生物技术有限公司 结合人TNFα的人抗体
CA2792122C (en) 1997-07-07 2015-09-08 Medical Research Council In vitro sorting method
GB9722131D0 (en) 1997-10-20 1997-12-17 Medical Res Council Method
WO1999058655A2 (en) 1998-05-13 1999-11-18 Diversys Limited Phage display selection system for folded proteins
IL127127A0 (en) 1998-11-18 1999-09-22 Peptor Ltd Small functional units of antibody heavy chain variable regions
JP2003523742A (ja) 2000-02-03 2003-08-12 ドマンティス リミテッド コンビナトリアルタンパク質ドメイン
US7148061B2 (en) 2000-02-11 2006-12-12 The United States Of America As Represented By The Department Of Health And Human Services Identification of a novel domain in the tumor necrosis factor receptor family that mediates pre-ligand receptor assembly and function
US7265210B2 (en) * 2000-09-15 2007-09-04 Genentech, Inc. Anti-PRO9821 antibodies
JP4434580B2 (ja) 2000-11-28 2010-03-17 メディミューン，エルエルシー 予防及び治療のために抗ｒｓｖ抗体を投与／処方する方法
WO2004058821A2 (en) * 2002-12-27 2004-07-15 Domantis Limited Dual specific single domain antibodies specific for a ligand and for the receptor of the ligand
US20060073141A1 (en) * 2001-06-28 2006-04-06 Domantis Limited Compositions and methods for treating inflammatory disorders
EP1399484B1 (en) 2001-06-28 2010-08-11 Domantis Limited Dual-specific ligand and its use
GB0118689D0 (en) * 2001-08-01 2001-09-19 Psimedica Ltd Pharmaceutical formulation
EP1572936A2 (en) 2002-03-05 2005-09-14 Eli Lilly And Company Heterologous g-csf fusion proteins
DK1517921T3 (da) 2002-06-28 2006-10-09 Domantis Ltd Immunglobulin-enkeltvariable antigen-bindende domæner og dobbeltspecifikke konstruktioner deraf
US20060002935A1 (en) * 2002-06-28 2006-01-05 Domantis Limited Tumor Necrosis Factor Receptor 1 antagonists and methods of use therefor
US7696320B2 (en) * 2004-08-24 2010-04-13 Domantis Limited Ligands that have binding specificity for VEGF and/or EGFR and methods of use therefor
NZ605429A (en) 2002-09-06 2014-08-29 Amgen Inc Therapeutic human anti-il-1r1 monoclonal antibody
WO2004022096A1 (en) 2002-09-06 2004-03-18 Alexion Pharmaceuticals, Inc. Method of treatment of asthma using antibodies to complement component c5
JP2006520584A (ja) 2002-11-08 2006-09-14 アブリンクス エン．ヴェー． 安定化単一ドメイン抗体
GB0230203D0 (en) * 2002-12-27 2003-02-05 Domantis Ltd Fc fusion
US20060104968A1 (en) * 2003-03-05 2006-05-18 Halozyme, Inc. Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminogly ycanases
DK1639011T3 (da) * 2003-06-30 2009-02-16 Domantis Ltd Pegylerede enkelt-domæne antistoffer (dAb)
DK1729795T3 (en) 2004-02-09 2016-04-11 Human Genome Sciences Inc Albumin fusion proteins
SI1737962T1 (sl) 2004-03-24 2011-01-31 Domantis Ltd Univerzalni signalni peptid GAS1
EP2311433A3 (en) * 2004-10-21 2011-08-10 Genentech, Inc. Method for treating intraocular neovascular diseases
CA2588892A1 (en) 2004-12-02 2006-06-08 Dormantis Limited Anti-il-1r1 single domain antibodies and therapeutic uses
GB0521621D0 (en) * 2005-10-24 2005-11-30 Domantis Ltd Tumor necrosis factor receptor 1 antagonists for treating respiratory diseases
CA2632866A1 (en) * 2005-12-01 2007-06-07 Domantis Limited Noncompetitive domain antibody formats that bind interleukin 1 receptor type 1
EA200801166A1 (ru) * 2005-12-01 2008-12-30 Домантис Лимитед Форматы конкурентного доменного антитела, которые связываются с рецептором интерлейкина 1 первого типа
EP2068889B1 (en) 2006-08-10 2019-10-23 Roy C. Levitt Anakinra for use in the treatment of bronchiolitis obliterans syndrome
WO2008049897A1 (en) * 2006-10-27 2008-05-02 Ablynx N.V. Intranasal delivery of polypeptides and proteins
SG182170A1 (en) 2007-06-06 2012-07-30 Domantis Ltd Polypeptides, antibody variable domains and antagonists
CA2683791A1 (en) 2007-06-06 2008-12-11 Domantis Limited Polypeptides, antibody variable domains & antagonists

Also Published As

Publication number Publication date
KR20100018040A (ko) 2010-02-16
US8398979B2 (en) 2013-03-19
DK2162467T3 (en) 2015-08-24
TW200907128A (en) 2009-02-16
SG182151A1 (en) 2012-07-30
SG182141A1 (en) 2012-07-30
EP2746291A3 (en) 2014-09-03
IL202204A0 (en) 2010-06-16
CA2688447C (en) 2016-11-08
MX2009013211A (es) 2010-04-09
CA2688447A1 (en) 2008-12-11
PE20090323A1 (es) 2009-04-20
KR20100040841A (ko) 2010-04-21
SI2162467T1 (sl) 2015-11-30
CN101802004A (zh) 2010-08-11
US20110256122A1 (en) 2011-10-20
WO2008149149A3 (en) 2009-04-02
EA200901495A1 (ru) 2010-10-29
PE20090322A1 (es) 2009-04-20
US20120134982A1 (en) 2012-05-31
US20100247515A1 (en) 2010-09-30
NZ581372A (en) 2012-02-24
CN101883788A (zh) 2010-11-10
CN101778865B (zh) 2016-11-09
EP2746291B1 (en) 2019-08-14
CN104311663B (zh) 2018-11-02
KR101604274B1 (ko) 2016-03-17
HUE025899T2 (en) 2016-05-30
TW200911831A (en) 2009-03-16
US20090148437A1 (en) 2009-06-11
PT2162467E (pt) 2015-10-29
MA31668B1 (fr) 2010-09-01
EP2746290A3 (en) 2014-09-10
BRPI0813899A2 (pt) 2019-09-24
JP2010530364A (ja) 2010-09-09
CA2688433A1 (en) 2008-12-11
JP5444215B2 (ja) 2014-03-19
AU2008259590A1 (en) 2008-12-11
CR11194A (es) 2010-06-28
TW200918088A (en) 2009-05-01
MA31403B1 (fr) 2010-05-03
CA2683791A1 (en) 2008-12-11
CA2688434A1 (en) 2008-12-11
PL2162467T3 (pl) 2015-12-31
ES2546943T3 (es) 2015-09-30
AR066848A1 (es) 2009-09-16
EP2746290B1 (en) 2019-08-14
EA200901494A1 (ru) 2010-06-30
JP5325211B2 (ja) 2013-10-23
MX2009013137A (es) 2010-04-30
AU2008259514B2 (en) 2014-05-15
EA201100546A1 (ru) 2011-12-30
EA200901300A1 (ru) 2010-06-30
CO6251322A2 (es) 2011-02-21
CL2008001674A1 (es) 2008-11-21
AU2008259514A1 (en) 2008-12-11
CY1116762T1 (el) 2017-03-15
WO2008149148A2 (en) 2008-12-11
KR20100041746A (ko) 2010-04-22
WO2008149148A3 (en) 2009-04-02
JP2010530220A (ja) 2010-09-09
ZA200908470B (en) 2011-02-23
EA200901491A1 (ru) 2010-08-30
MX2009012967A (es) 2010-04-01
CA2683823A1 (en) 2008-12-11
MX2009013138A (es) 2010-04-30
BRPI0812795B8 (pt) 2020-01-28
EP2746291A2 (en) 2014-06-25
AR066847A1 (es) 2009-09-16
DOP2009000268A (es) 2010-02-28
WO2008149150A2 (en) 2008-12-11
AU2008259515A1 (en) 2008-12-11
BRPI0812795C1 (pt) 2021-05-25
EP2164867A2 (en) 2010-03-24
EP2162467B1 (en) 2015-07-22
BRPI0812795B1 (pt) 2019-12-03
HK1138022A1 (en) 2010-08-13
WO2008149149A2 (en) 2008-12-11
BRPI0812268A2 (pt) 2019-09-10
EA018129B1 (ru) 2013-05-30
TW200902551A (en) 2009-01-16
HRP20151024T1 (hr) 2015-11-06
JP2010529841A (ja) 2010-09-02
EA018723B1 (ru) 2013-10-30
EP2746290A2 (en) 2014-06-25
TW200911832A (en) 2009-03-16
EP2162467A2 (en) 2010-03-17
CN101778865A (zh) 2010-07-14
CA2688456A1 (en) 2008-12-11
BRPI0812795A2 (pt) 2014-12-02
IL201398A0 (en) 2010-05-31
CN104311663A (zh) 2015-01-28
CL2008001673A1 (es) 2008-11-21
US20100266616A1 (en) 2010-10-21
KR20100021642A (ko) 2010-02-25
CR11195A (es) 2010-05-24
AR066850A1 (es) 2009-09-16
CO6251321A2 (es) 2011-02-21
CL2008001676A1 (es) 2008-11-21
EP2162468A2 (en) 2010-03-17
TW200911834A (en) 2009-03-16
AU2008259516A1 (en) 2008-12-11
WO2008149150A3 (en) 2009-06-25

Similar Documents

Publication Publication Date Title
PE20090763A1 (es) Polipetidos, dominios variables de anticuerpos y antagonistas
CY1125427T1 (el) Anti-gm-csf αντισωματα και χρησεις αυτων
PE20191551A1 (es) Polipeptidos de union al receptor de transferrina disenados
AR063090A1 (es) Proteinas de union al antigeno del receptor de la il-17
PE20211272A1 (es) POLIPEPTIDOS DE IL-22 Y PROTEINAS DE FUSION DE IL-22 Fc Y METODOS DE USO
CR11193A (es) Polipeptidos, dominios variables de anticuerpos y antagonistas
HRP20150664T1 (hr) Antikancerogeni fuzijski protein
ATE469913T1 (de) Antagonisten des nogo-rezeptors
GT200600065A (es) Anticuerpos para interleucina-17f y otros antagonistas de la señalizacion de il-17f y sus usos
CL2008002668A1 (es) Anticuerpo que se une especificamente al polipeptido de linfopoyetina estromal timica (tslp); composicion farmaceutica que lo comprende; acido nucleico, vector de expresion, celula que lo comprende; hibridoma; metodo de produccion del anticuerpo; uso para tratar desorden inflamatorio relacionado a tslp o condicion fibrotica relacionada a tslp.
MX2016008355A (es) Anticuerpos que comprenden extensiones de polipeptidos de cadena ligera en el extremo c y conjugados y metodos de uso de estos.
PE20180502A1 (es) Composiciones anti-cgrp y uso de las mismas
CR20130112A (es) Polipéptidos que enlazan miostatina, composiciones y métodos
AR058955A1 (es) Inmunglobulinas que se unen a interleuquina 13
HRP20170905T1 (hr) Antikancerogeni fuzijski protein
MX377605B (es) Inmunoglobulina híbrida conteniendo un enlace no-peptidílico.
PE20121564A1 (es) Polipeptidos anti-tnfr1 estables, dominios variables de anticuerpos y antagonistas
CL2011000975A1 (es) Anticuerpo o fragmento del mismo que se une a al menos un residuo de animoacido del receptor tipo toll 3 (tlr3); composicion farmaceutica que lo comprende; su uso para tratar una condicion inflamatoria.
WO2007117577A3 (en) High affinity human antibodies to human il-18 receptor
EA201691780A1 (ru) Наноструктурированный песок, способ получения наноструктурированного песка, способ разделения смеси загрязняющее вещество-вода с помощью наноструктурированного песка и дополнительные применения
IS8339A (is) Mótlyf viðtaka NOGO
MX2021010404A (es) Anticuerpos que se unen a una forma escindida de calreticulina mutante, y agente de diagnostico, preventivo o terapeutico para las neoplasias mieloproliferativas.
UA117493C2 (uk) Гібридна конструкція, що включає антигенсполучний фрагмент, специфічний до сироваткового альбуміну, й ефекторний компонент, та способи її одержання
AR066311A1 (es) Moleculas de anticuerpos anti proteina hsp90 fungica y acidos nucleicos que los codifican
ATE498683T1 (de) Leptin antagonisten

Legal Events

Date Code Title Description
FC Refusal